DC661 CAS 1872387433 High Purity Manufacturer Suppliers in China Factory
DC661 (CAS NO. 1872387-43-3) is a high-potency pharmacological probe and selective inhibitor of palmitoyl-protein thioesterase 1 (PPT1) and PPT2. Designed for advanced oncology and cell biology research, this dimeric chloroquine derivative effectively disrupts lysosomal function and inhibits autophagic flux, making it an indispensable tool for investigating nutrient recycling and organelle clearance in malignant cells.
By neutralizing lysosomal pH and blocking the fusion of autophagosomes with lysosomes, DC661 triggers the accumulation of LC3B-II markers and induces apoptotic cell death. It is particularly effective in overcoming resistance to targeted therapies, such as BRAF/MEK inhibitors in melanoma, pancreatic, and colorectal carcinomas, providing researchers with a superior alternative to traditional agents like hydroxychloroquine.
Detailed Parameters
| Product Name | DC661 | CAS NO. | 1872387-43-3 |
|---|---|---|---|
| Molecular Formula | C31H39Cl2N5 | Molecular Weight | 552.58 g/mol |
| Appearance | White to off-white solid powder | Purity (RP-HPLC) | ≥98.0% |
| Solubility | Soluble in DMSO (>10 mg/mL), DMF | Endotoxin | < 10 EU/mg |
| Storage | -20°C, protected from light/moisture | MOQ | 1g |
Key Advantages
High Potency
Inhibits autophagic flux at concentrations 100 times lower than hydroxychloroquine (HCQ).
Selective Inhibition
Specifically targets PPT1/PPT2 within the acidic lysosomal environment to block depalmitoylation.
Tumor Suppression
Demonstrated near-complete suppression of tumor growth in HT29 colorectal xenograft models.
Superior Efficacy
Outperforms dimeric analogs like Lys05 in reducing cancer cell viability and clonogenic growth.
Immune Activation
Capable of activating alternative immune pathways, including STING signaling for oncology research.
Research Grade
Strictly validated purity (≥98%) ensuring reproducible results for in vitro and in vivo studies.
Product Gallery
Management Platforms
GMP Compliance
Production partners utilize GMP-compliant systems for standardized raw material procurement.
Quality Control
Strict QC processes covering synthesis, purification, and MS chromatogram testing.
Full Documentation
Each batch is delivered with COA, HPLC purity reports, and third-party validation.
Global Logistics
Secure air freight via DHL, FedEx, and UPS to ensure product stability and speed.
Batch Traceability
Comprehensive traceability and stability data for every synthesized lot.
Custom Scale
Flexible supply capabilities ranging from gram-level research to ton-level industrial production.
Investment Return Comparison
| Performance Metric | Hydroxychloroquine (HCQ) | DC661 (Our Product) |
|---|---|---|
| Potency (IC50) | Standard Baseline | 100x Higher Potency |
| Autophagic Inhibition | Moderate Flux Block | Superior Flux Disruption |
| Tumor Growth Reduction | Partial Inhibition | Near Complete Suppression |
| Systemic Toxicity | Variable | Low/Well Tolerated |
| Clonogenic Growth | Moderate Suppression | Strongly Inhibited |
Frequently Asked Questions
DC661 is primarily used as a pharmacological probe to study autophagy dependence in malignant cells, specifically for overcoming resistance to targeted therapies in melanoma and colorectal cancer research.
DC661 is significantly more potent, inhibiting autophagic flux at concentrations 100 times lower than HCQ and demonstrating superior efficacy in reducing cancer cell viability.
For maximum stability, DC661 should be stored at -20°C, protected from light and moisture, in a tightly sealed container.
No, this compound is indicated strictly for non-clinical, in vitro, and in vivo research applications only.
Every batch comes with a Certificate of Analysis (COA), RP-HPLC purity reports, and mass spectrometry (MS) chromatograms to ensure pharmaceutical-grade quality.
DC661 is soluble in DMSO (at concentrations >10 mg/mL) and DMF, but it is insoluble in water.
Request High-Purity DC661 for Your Research
Contact Us
